They showed that piR-FTH1 downregulates Fth1 mRNA in triple-negative breast cancer (TNBC) cells, namely, MDA-MB-231, which indicates a potential therapeutic strategy for reducing FTH1 levels in cancer cells (Balaratnam et al., 2018). This evidence concerns the gene PIR and cancer.